Overview

Chemoprevention of Oral Premalignant Lesions

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
Reduction in size and number of oral premalignant lesions
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Celecoxib